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Abstract
Cerebrospinal fluid (CSF) biomarkers T-Tau and Ab42 are linked with Alzheimer’s disease (AD), yet little is known about the
relationship between CSF biomarkers and structural brain alteration in healthy adults. In this study we examined the extent
to which AD biomarkers measured in CSF predict brain microstructure indexed by diffusion tensor imaging (DTI) and
volume indexed by T1-weighted imaging. Forty-three middle-aged adults with parental family history of AD received
baseline lumbar puncture and MRI approximately 3.5 years later. Voxel-wise image analysis methods were used to test
whether baseline CSF Ab42, total tau (T-Tau), phosphorylated tau (P-Tau) and neurofilament light protein predicted brain
microstructure as indexed by DTI and gray matter volume indexed by T1-weighted imaging. T-Tau and T-Tau/Ab42 were
widely correlated with indices of brain microstructure (mean, axial, and radial diffusivity), notably in white matter regions
adjacent to gray matter structures affected in the earliest stages of AD. None of the CSF biomarkers were related to gray
matter volume. Elevated P-Tau and P-Tau/Ab42 levels were associated with lower recognition performance on the Rey
Auditory Verbal Learning Test. Overall, the results suggest that CSF biomarkers are related to brain microstructure in healthy
adults with elevated risk of developing AD. Furthermore, the results clearly suggest that early pathological changes in AD
can be detected with DTI and occur not only in cortex, but also in white matter.
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Introduction
Distinguishing pathologically aging elders from those who will
age normally is a key challenge in preventing Alzheimer’s disease
(AD). Several cerebrospinal fluid (CSF) markers that are presum-
ably related to the core pathology in AD show promise for early
detection of the disease. Lower levels of CSF Ab42, higher CSF
total tau (T-Tau), and higher tau phosphorylated at threonine 181
(P-Tau181), as well as biomarker ratios (T-Tau/Ab42 or P-Tau/
Ab42) distinguish patients from controls [1,2,3,4,5] and predict
conversion from mild cognitive impairment (MCI) to AD
[1,2,6,7,8,9]. When evaluated in cognitively healthy individuals,
these biomarkers also appear to be related to cognitive function
[10,11], and measures of brain health that include cortical
thinning [12], ventricular expansion and atrophy
[11,13,14,15,16].
While studies resulting from volumetric imaging have been very
useful for revealing gross structural changes, it is possible that
some of the earliest brain changes involved in AD are subtle and
below the detection threshold for volumetric imaging. Sensitive to
water molecule motion, maps derived from diffusion tensor
imaging (DTI) [17] provide unique information on brain
microstructure. Mean diffusivity (MD) provides an index of
isotropic diffusion of water molecules, and fractional anisotropy
(FA) provides a measure of the degree of diffusion anisotropy, both
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of which may be altered by tissue damage. Maps based on the
principal diffusivities that compose the diffusion tensor may
provide additional information on microstructural alterations. The
principal diffusivity (l1), or axial diffusivity, represents water
diffusion that is parallel to axons and may be altered by axonal
injury; radial diffusivity (an average of l2 and l3), represents
water diffusion that is perpendicular to axonal fibers and is thus
linked to the microstructure of myelin
[18,19,20,21,22,23,24,25,26]. DTI has been used to measure
disease-related changes in patients with AD
[27,28,29,30,31,32,33,34,35,36,37,38,39], as well as alterations
in people with MCI [37,40,41,42,43,44,45,46]. Using DTI,
microstructural differences have also been detected in presumed
presymptomatic AD including participants with APOE4 genotype
[47,48,49] family history of AD [50,51], or a combination of both
risk factors [52].
In the present study, we examined the relationship between
brain microstructure indexed by DTI and proteins associated with
brain health in CSF collected in healthy middle-aged and older
adults from the Wisconsin Registry for Alzheimer’s Prevention
[53]. Additionally, because T1-weighted imaging may inform
upon atrophy, we assessed the extent to which biomarkers in CSF
were related to volume as assessed via T1-weighted imaging.
Based on their utility in distinguishing AD patients from controls
[1,2,3,4,5], the CSF biomarkers considered in this study were T-
Tau, P-Tau181, and Ab42. In addition to these markers of AD
pathology, we analyzed CSF for a structural protein of neurons
that is predominantly localized in large-caliber axons (and thus
likely sensitive to axonal degeneration in white matter): neurofil-
ament light chain protein (NFL) [54]. We hypothesized that
baseline CSF measures of these markers would be related to brain
health as measured with DTI, especially in brain regions that are
affected early in the AD process–principally temporal and
cingulate gray and white matter. We expected higher T-Tau
and P-Tau and lower Ab42 in CSF would be related to lower FA,
higher MD, and altered radial and axial diffusivity in AD-sensitive
brain regions. Additionally, we expected that NFL, being sensitive
to axonal alteration, would be especially related to axial
diffusivity–reflecting altered axonal health. Although the brain
regions affected in AD are well known, the relationship between
CSF biomarkers and brain health is a relatively new area of study,
accordingly we used voxel-wise analyses (corrected for multiple
comparisons) [55] to assess relationships across the entire brain.
Materials and Methods
Study procedures were approved by the University of Wisconsin
Health Sciences Institutional Review Board and were in accor-
dance with U.S. federal regulations. All participants provided
written informed consent.
Participants
We enrolled 47 participants, four of whom were excluded due to
unexpected abnormalities found on their MRI scan by the
reviewing radiologist (HAR). The remaining 43 middle- to older-
aged participants were 37 years of age to 66 years of age at time of
lumbar puncture and CSF collection (mean= 53.67, SD=7.77);
and 42 to 71 years of age at time of follow-up scan (mean= 57.61,
SD=8.03). There were 12 men and 31 women. As a group,
participants were well educated (mean=16.26 years, SD=2.60).
All participants were from the Wisconsin Registry for Alzheimer’s
Prevention (WRAP) [53] and had at least one parent with AD.
WRAP is a registry of cognitively normal adults who are followed
longitudinally and comprise individuals who have at least one
parent with late onset AD and a group of controls with no family
history of AD [53]. To verify the diagnosis of AD in parents of
WRAP participants, parental medical records (and autopsy reports
where available) were reviewed by a multidisciplinary diagnostic
consensus panel. A diagnosis of AD in parents was made using
standard clinical criteria [56,57]. There were no families included
with known autosomal dominant mutations. In the final sample,
three participants had parents who were diagnosed with AD at
autopsy, while the remaining clinical diagnoses were confirmed
during a consensus meeting. Twelve participants (28%) were
carriers of the e4 allele of the apolipoprotein E (APOE4) gene.
Inclusion criteria for all subjects consisted of the following: prior
visit for lumbar puncture, normal cognitive function determined
by neuropsychological evaluation, no contraindications for MRI
and a subsequent normal MRI scan, no current diagnosis of major
psychiatric disease or other major medical conditions (e.g.,
diabetes, myocardial infarction, or recent history of cancer), and
no history of head trauma.
Neuropsychological Testing
As part of their participation in WRAP, participants received at
least one comprehensive neuropsychological assessment. Neuro-
psychological testing occurred an average of 1.80 years (SD=1.28
years) out from the MR scan and 2.06 years (SD=1.20 years) out
from their lumbar puncture. In order to screen for changes in
cognitive status, participants who were .3 months out from a
neuropsychological testing visit also received the Mini Mental
State Examination (MMSE) [58] upon the day of scan. We
prospectively identified a subset of tests to examine memory,
executive function, and speed of processing. These tests were
BVMT (Brief Visuospatial Memory Test, Revised) total raw score, and
delayed recall, which index visuospatial learning and memory
[59]; COWAT (Controlled Oral Word Association Test; [60])
seconds to complete/raw score, to assess verbal fluency; Trail
Making Test A & B, to assess motor speed, sequencing, and
vigilance and in Trails B, the additional functions of rapid set
shifting, serial retention and integration, verbal problem solving,
and planning [61]; Wechsler Adult Intelligence Scale Working
Memory Index–a composite of arithmetic, digit span, and letter
number sequencing [62]–to assess the ability to hold information
in working memory; RAVLT (Rey Auditory Verbal Learning test) total
over the five learning trials, recognition, and 20 minute delayed
recall raw scores [63] to assess immediate and delayed verbal
memory.
CSF Collection
The CSF collection was performed via lumbar puncture at a
baseline visit in a simvastatin trial [64] an average of 3.41 years
prior to brain imaging (SD=1.19 yrs). CSF samples were
collected in the morning after a 12-hour overnight fast, aliquoted
in sterile polypropylene collection tubes, and stored in a 280uC
freezer. The samples were subsequently sent in one batch to the
Sahlgrenska University Hospital at the University of Gothenburg
in Sweden for analysis. CSF T-Tau, P-Tau181, and Ab42 analysis
was accomplished via xMAP technology and utilizing the INNO-
BIA AkzBio3 kit (Innogenetics) as previously described [65]. The
xMAP technology is based on flow cytometric separation of
antibody-coated microspheres that are labeled with a specific
mixture of two fluorescent dyes. xMAP allows for simultaneous
measurement of several analytes in the same tube, has low intra-
and inter-assay variability, and high reproducibility even at low
concentrations. NFL was analyzed using the sandwich ELISA
method described in [66] with a limit of quantification of 125 ng/
L. All analyses were performed on one occasion by certified
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laboratory technicians. Intra-assay coefficients of variation were
below 10% for all analytes.
Magnetic Resonance Imaging
Participants were invited for brain imaging on the condition
that baseline CSF samples were available for analysis. Participants
were imaged on a General Electric 3.0 Tesla Discovery MR750
(Waukesha, WI) MRI system with an 8-channel head coil and
parallel imaging (ASSET). DTI was acquired using a diffusion-
weighted, spin-echo, single-shot, echo planar imaging pulse
sequence in 40 encoding directions, B0= 1300, with eight non-
diffusion weighted reference images. The cerebrum was covered
using contiguous 2.5 mm thick axial slices, FOV=24 cm,
TR=8000, E= 67.8, matrix = 96696, resulting in isotropic
2.5 mm voxels. High order shimming was performed prior to
the DTI acquisition to optimize the homogeneity of the magnetic
field across the brain and to minimize EPI distortions. A T1-
weighted volume was acquired in the axial plane with a 3D fast
spoiled gradient-echo (3D EFGRE) sequence using the following
parameters: TI= 450 ms; TR=8.1 ms; TE=3.2 ms; flip an-
gle = 12u; acquisition matrix = 25662566156, FOV=260 mm;
slice thickness = 1.0 mm.
MRI Processing
Diffusion-weighted DICOM images were converted into NIFTI
format using AFNI (http://afni.nimh.nih.gov/). FA, MD, and
lambda maps (l1, l2 & l3) were generated via the FMRIB
Software Library (FSL) (http://www.fmrib.ox.ac.uk/fsl/fdt/
index.html using the following procedures: (1) image distortions
in the DTI data caused by eddy currents were corrected; (2)
estimation of diffusion tensors was achieved using DTIFIT; (3)
three-dimensional maps of FA, MD, and the 3 eigenvalues (l1, l2
& l3) were computed from the tensors from step (2). Each
participant’s FA map was aligned to an FA template in Montreal
Neurological Institute (MNI) space, comprised of an average of
121 FA maps acquired from healthy participants with similar
demographics as the study cohort. Transformations were achieved
via 12-parameter affine transformation and nonlinear deformation
using Statistical Parametric Mapping software (SPM8 available at
http://www.fil.ion.ucl.ac.uk/spm). Estimated transforms from
each participant’s FA map warping were applied to the
participant’s remaining DTI maps (MD, l1, l2 & l3) resulting
in a transformation of all the original images into MNI space. The
normalized FA maps were used to visually inspect for accurate
normalization using the ‘‘check registration’’ function in SPM and
selecting specific fiber tracts for comparison (corpus callosum,
cingulum, superior longitudinal fasciculus). l2 & l3 maps were
averaged to create radial diffusivity maps, and l1 was the axial
diffusivity map.
Processing of the T1-weighted images was performed using a six
class segmentation tool in SPM8. Processing involved bias
correction and iterative normalization and segmentation of the
original anatomic images [67] into distinct tissue classes (gray
matter, white matter, cerebrospinal fluid, skull, fat tissue, and
image background) using spatial prior information. Gray matter
tissue segments were normalized to MNI template space via a 12-
parameter affine transformation and nonlinear deformation (with
a warp frequency cutoff of 25). The segmented and normalized
gray matter maps were ‘‘modulated’’, which involves scaling the
final gray matter maps by the amount of contraction or expansion
required to warp the images to the template. The final result was a
gray matter probability map for each participant in which the total
amount of gray matter remained the same as in the original
images. The spatially normalized gray matter maps were
smoothed using an 8-mm Gaussian kernel before being entered
into the statistical analysis.
Statistical Analysis
In order to test the relationship between CSF proteins, age, and
cognitive function, we performed linear correlation analysis using
SPSS (Release 19.0.0, Chicago, SPSS Inc.). CSF biomarkers were
log transformed to normalize distribution prior to inclusion in
analysis. Differences in CSF protein levels based on APOE status
and gender were tested using independent t-tests in SPSS. In order
to test the extent to which CSF biomarkers were associated with
brain health as indexed by the DTI maps and T1-weighted
imaging, voxel-wise linear regression models were implemented
via statistical modules available in SPM8. The independent
variables were Ab42, total tau (T-Tau), phosphorylated tau (P-
Tau181), T-Tau/Ab42, and P-Tau181/Ab42, while the dependent
variables consisted of participants’ DTI maps and gray matter
probability maps. Due to relatively low levels of NFL in the
majority of participants (NFL,125 ng/L; N= 33), NFL was
treated as a categorical variable. The detection limit of the assay is
NFL,125 ng/L, thus we used this as a cut-point to determine the
groups. Differences in brain health based on NFL was tested using
voxel-wise ANCOVA, where DTI maps or gray matter probability
maps were the dependent variable and the groups were
NFL.125 ng/L, and NFL,125 ng/L. Age (at time of MR scan)
and gender were included as covariates in all models due to known
effects on brain microstructure [68,69,70,71]. Because the imaging
was performed in a group of participants that had been
randomized in a simvastatin trial, only baseline (pre-simvastatin)
CSF measures were used and a treatment vs. placebo covariate
was included in the statistical models. All analyses were
thresholded at p,.05 corrected for multiple comparisons using
false discovery rate (FDR) correction [72]. In order to exclude
small clusters and increase the anatomical plausibility of the
results, a cluster size threshold of 50 contiguous voxels was used
and analyses were restricted to gray and white matter using a
binary brain mask. The binary brain mask was computed by
thresholding the SPM brain mask in MNI space (which contains
voxels that vary from 0 percent to 100 percent probability of brain)
at a threshold of.5 or greater (50% probability or greater of being
brain). Furthermore, analysis of the gray matter probability maps
used an absolute threshold masking of 0.1 to exclude voxels with a
low probability of being gray matter.
Results
Demographics, Neuropsychological Function, and CSF
Biomarkers
There was a significant positive correlation (P,.05) between age
at time of lumbar puncture and T-Tau, T-Tau/Ab42, and P-
Tau181/Ab42 (Pearson correlation coefficients for age and CSF
markers are shown in Table 1). Men and women did not differ on
CSF biomarker levels of T-Tau, P-Tau181, Ab42, T-Tau/Ab42, or
P-Tau181/Ab42. There was a significant difference in T-Tau and
Ab42 between APOE4 positive and APOE4 negative participants,
where T-Tau was higher in the non-carriers (m=4.25) compared
to carriers (m=3.90), t(41) = 2.038, p,.05, and Ab42 was lower in
the carriers (m= 5.57) compared to non-carriers (m=5.83),
t(41) = 3.062, p,.05. APOE4 carriers and non-carriers did not
differ on age (p = .78).
All participants were cognitively normal as determined by
comprehensive neuropsychological testing and as assessed by
MMSE (MMSE $27). Controlling for age and education, linear
correlation analysis indicated that baseline CSF biomarker levels
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were related to a subset of the neuropsychological test scores.
WAIS Working Memory Index (scaled for age and education) was
positively correlated with T-Tau (r = .307, p,.05) and with T-
Tau/Ab42 (r = 0.303, p = .051). However, a scatter-plot revealed
that the participant with the highest tau value (.2 SD higher than
the mean) performed well on working memory–skewing the
results. When this participant was removed from the analysis, the
relationships were no longer significant. RAVLT recognition score
was negatively correlated with both P-Tau181 (r =2.379, p,.05)
and P-Tau181/Ab42 (r =2.362, p,.05) but was not related to T-
Tau, Ab42, or their ratio. No other RAVLT sub-scores or other
neuropsychological tests were significantly correlated with the CSF
markers.
Imaging Results
Voxel-wise regression analysis indicated that both T-Tau and
T-Tau/Ab42 showed robust and widespread positive relationships
with several of the DTI measures, specifically MD, axial and radial
diffusion. These relationships were extensive in white matter and
were prevalent in temporal, parietal and frontal lobes. The
locations of peak T-value for MD and FA clusters obtained in the
voxel-wise analysis are tabulated in Table 2 (axial and radial
diffusivity results are tabulated in Table S1). The brain regions
where CSF T-Tau/Ab42 predicted MD values in the voxel-wise
regression analysis are shown in Figure 1; the positive relation-
ship between T-Tau/Ab42 and MD is shown in Figure 2 in
scatter plots from a subset of the significant clusters found in the
voxel-wise regression analysis. The regional overlap between T-
Tau and T-Tau/Ab42 SPM result maps (MD, axial and radial
diffusivity) was extensive, and is summarized in terms of percent
overlap in Table 3.
At a statistical threshold of p,.05 (FDR corrected for multiple
comparisons) there was no relationship between T-Tau or T-
Tau/Ab42 and FA. Furthermore, neither P-Tau181 nor P-Tau/
Ab42 were related to any of the DTI measures (FA, MD, axial or
radial diffusivity). Higher Ab42 in CSF was related to higher FA
in medial frontal gyrus, but not related to MD, axial or radial
diffusivity. Participants with NFL.125 ng/L showed a single
region of higher FA in middle temporal gyrus white matter
compared to control, with no differences in MD, axial or radial
diffusivity. Complete results (cluster extent, T-value, and
locations) for all CSF measures and FA and MD maps are in
Table 2 (axial and radial diffusivity results are tabulated in
Table S1). None of the CSF biomarkers predicted gray matter
volume as indexed by the modulated gray matter probability
maps (FDR p,.05).
Discussion
General
AD-related CSF biomarkers are linked with global and regional
brain volumes in healthy elderly [12,13,14]. In this study, we
assessed the relationship between brain tissue microstructure
measured with DTI and AD-related CSF biomarkers. Addition-
ally, we assessed the relationship between CSF biomarkers and
gray matter volume. Our group has previously found that
cognitively healthy people with parental family history of AD
show microstructural brain differences compared to those without
risk for AD [50]. In this study, we found that CSF biomarkers
previously associated with AD are related to brain tissue
microstructure in similar regions as those previously found to be
associated with parental family history.
While gray matter volume was not related to any of the CSF
biomarkers in this study, CSF biomarkers were related to white
matter health as indexed by DTI; interestingly, the regions of
significant association were mostly adjacent to critical gray matter
structures that are known to be affected in AD. This was especially
true for T-Tau and T-Tau/Ab42, where higher CSF levels were
related to higher axial, radial, and mean diffusivity in a large
swath of temporal lobe white matter adjacent to hippocampus.
Several studies now point toward early involvement of white
matter in AD development, including human studies on AD risk
[48,49,50,52,73], and studies on a triple transgenic mouse model
of AD indicating white matter changes may precede other
measurable pathology in AD [74,75]. In contrast, studies
conducted in AD and memory impaired patients have found that
CSF biomarker levels are related to gray matter structures
including hippocampus, entorhinal cortex [76], and posterior
cingulate cortex [77], One possibility is that early AD pathology
involves axonal or myelin degeneration and that cortical change is
only measurable at later disease stages or in more elderly
individuals.
White Matter Degeneration in AD: Myelin and Axons
White matter degeneration in diagnosed AD is confirmed by
several human post mortem studies [78,79,80,81]. MRI enabled
ante mortem studies substantiate post mortem findings, showing
decreased regional white matter volumes in AD compared to
controls [82,83,84,85,86,87,88,89,90,91,92] and differences in
water diffusion properties in white matter
[27,28,29,30,31,32,33,34,35,36,37,93]. White matter alterations
in confirmed AD are a combination of axonal and myelin
alteration, yet it is unknown whether white matter changes are
secondary to damage of the neuronal soma, involve primary axonal
Table 1. Linear correlation among CSF biomarkers and age.
Age T-Tau P-Tau181 Ab42 T-Tau/Ab42
Age Pearson Correlation
T-Tau Pearson Correlation 0.367 *
P-Tau181 Pearson Correlation 0.253 0.585 T-
Ab42 Pearson Correlation 20.147 0.256 0.228
T-Tau/Ab42 Pearson Correlation 0.443 * 0.856 T- 0.459 * 20.281
P-Tau181/Ab42 Pearson Correlation 0.326 * 0.436 * 0.854 T- 20.310 * 0.599 T-
Significant correlation at P,.05 *.
Significant at p,.001 T-.
doi:10.1371/journal.pone.0037720.t001
AD Biomarkers in CSF and WM Microstructure
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e37720
degeneration [94,95], are linked with myelin degeneration
[39,46,96,97,98], or represent some combination of these events.
In our study we measured the relationship between CSF
biomarkers and DTI measures that are presumably related to
axonal health (axial diffusivity) and myelin health (radial
diffusivity). We found that both T-Tau and T-Tau/Ab42 predicted
axial and radial diffusivity, suggesting these CSF biomarkers are
potentially related to both neuronal axon integrity and health of
oligodendrocyte synthesized myelin. Furthermore, the analyses of
axial, radial, and mean diffusivity produced statistical maps that
were highly overlapping, suggesting that alterations in one cell
component (e.g. neuronal axons) could very well be associated
with related alterations in another cell component (myelin).
Although CSF measures of myelin were not available to us in
this study, we assessed axonal degeneration via CSF measured
neurofilament light protein. Neurofilament proteins are major
constituents of the axonal cytoskeleton, consisting of three
polypeptides; light (NFL), medium and heavy subunits. NFL
proteins are most related to large-caliber axons [99] and when
axons are damaged, NFL is released into CSF. NFL proteins
measured in CSF are significantly higher in AD compared to
controls [66,100,101,102,103,104]. In our study,a group compar-
ison based on CSF NFL levels yielded a single region of difference
in middle temporal gyrus white matter, where participants with
higher CSF NFL showed higher FA. Although we expected that
the group with presumably greater axonal degeneration would
show lower FA, it’s possible that early stage axonal degeneration in
the presence of intact myelin could lead to higher anisotropy.
Another possibility is a loss of crossing fibers in this region–which
could lead to higher FA. Although we did not find a relationship
between CSF NFL and the mean, radial, and axial diffusivity maps
at a relatively conservative statistical threshold, analyses performed
at uncorrected (for multiple comparisons) thresholds did show
differences between NFL groups. Interestingly, the group with
higher CSF NFL showed higher axial diffusivity in cingulum and
white matter adjacent to hippocampus. Because only ten
participants in our study had NFL levels greater than the detection
limit of 125 ng/L, we were likely underpowered to find these
subtle differences at corrected thresholds and further work will be
needed to expand upon these preliminary findings.
Classic Pathology: Abnormal Phosphorylation of Tau and
Amyloid Deposition
In AD, abnormal phosphorylation of tau protein and deposition
of amyloid are considered primary processes underlying neuronal
degeneration. Hyperphosphorylation of tau and its subsequent
release from the cell means markers of tau measured in CSF
increase compared to controls [105]. In contrast, CSF markers of
Figure 1. CSF T-Tau/Ab42 and mean diffusivity. Higher T-Tau/Ab42 at baseline was associated with increased mean diffusivity in follow-up
scanning in several brain regions, encompassing both gray and white matter. As shown above, this relationship was especially prominent in temporal
lobe white matter adjacent to hippocampus, but also encompassing gray and white matter in frontal and parietal lobes, portions of occipital white
matter, and small clusters in cerebellum. Results are FDR corrected for multiple comparisons (p,.05) and displayed here with a cluster size threshold
of 20 or more voxels. Sections are shown in sagittal view beginning from the left side of the brain to right. Variations in the color map reflect the size
of the T-statistic (indexed by the color bar at bottom).
doi:10.1371/journal.pone.0037720.g001
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amyloid decrease as amyloid is deposited in the brain
[3,4,106,107]. In our study, we found widespread relationships
between elevated CSF T-Tau and altered measures of brain tissue
microstructure indexed by mean, radial, and axial diffusivity, with
somewhat similar but also distinctive patterns occurring for T-
Tau/Ab42 (up to 70% overlap in the radial diffusivity maps).
Although the localized source of tau protein measured in CSF is
unknown, higher levels in our study were related to higher
diffusion across temporal, parietal, and frontal lobes–particularly
in white matter. We speculate CSF tau protein may have
originated from axons in these brain regions, but we can not rule
out that tau may have also originated from oligodendroglia [108].
Phosphorylation of tau is associated with the development of glial
tangles in human patients with AD [109,110,111], as well as in
animals expressing mutant tau [112,113,114]. Interestingly, CSF
levels of tau phosphorylated at threonine 181 did not show a
relationship with any of the DTI measures at the p,.05FDR
threshold. Although some studies suggest that CSF P-Tau181 does
not correlate with neuropathological burden in AD [115], in our
study it is possible that the relationship between P-Tau181 and
tissue microstructure was too subtle to survive our statistical
threshold. Indeed, when we performed exploratory analyses at
uncorrected (for multiple comparisons) thresholds, higher P-
Tau181 was associated with altered tissue microstructure. Further-
more, P-Tau181 and P-Tau181/Ab42 were the only biomarkers
related to memory function in this study. Nonetheless, considering
alternative sites of tau phosphorylation will likely be important for
understanding early AD and in AD biomarker development.
While T-Tau and T-Tau/Ab42 showed widespread relation-
ships with the DTI measures, CSF Ab42 was associated with lower
anisotropy of water (FA) only in medial frontal cortex and
underlying white matter. Deposition of brain amyloid in AD likely
involves frontal involvement at the earliest stages [116], which
presumably could have resulted in altered tissue microstructure in
this study. Studies using amyloid imaging in this cohort are
Figure 2. T-Tau/Ab42 Plotted against mean, radial, and axial diffusivity. Shown here are the results of the voxel-wise analysis, where regions
with color overlay are those where higher T-Tau/Ab42 was associated with higher diffusivity (mean, radial, and axial). In order to illustrate the
relationship between T-Tau/Ab42 and the diffusivity maps, we extracted diffusion values from representative regions of significant correlation in the
voxel-wise analysis and plotted them against T-Tau/Ab42. Shown on the top row are diffusion values extracted from the left temporal lobe (x =242,
y =234, z =216) plotted against T-Tau/Ab42. In the middle row are diffusion values extracted from right posterior cingulum bundle (x = 8, y =246,
z = 16) plotted against T-Tau/Ab42. In the bottom row are diffusion values extracted from left inferior frontal white matter (x =222, y = 43, z =212)
plotted against T-Tau/Ab42. Blue crosshairs overlaid on the brain sections indicate the location of the extracted values. Each point in the scatter
represents diffusion values from one participant (n = 43). T-Tau/Ab42 values were log-transformed and mean, radial, and axial diffusivity values were
adjusted for age at time of scan, sex, and treatment (CSF data were collected at baseline in a Simvastatin treatment trial, data from the prevention
trial are not shown here).
doi:10.1371/journal.pone.0037720.g002
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Table 2. Regions where CSF biomarkers were significantly correlated with FA and MD in the voxel-wise analyses.
MNI coordinates
x y z Peak T value k (mm3)
T-Tau & Fractional Anisotropy 6 6 6
T-Tau & Mean Diffusivity
R Parietal Lobe WM 26, 259, 42 7.89 13890
R Medial Frontal Gyrus 16, 7, 52 6.37 478
L Middle Frontal Gyrus 224, 43, 214 5.83 259
R Middle Temporal Gyrus 58, 242, 21 5.33 159
L Frontal Lobe, WM 218, 24, 59 5.25 154
R Corpus Callosum 12, 245, 12 5.23 414
R Medial Frontal WM 12, 46, 218 5.21 207
L Superior Temporal Gyrus WM 260, 223, 7 4.73 112
R Lentiform Nucleus, Putamen 26, 29, 7 4.45 256
R Superior Temporal Gyrus WM 60, 224, 21 4.39 145
L Temporal Lobe WM 252, 213, 221 4.37 143
L Inferior Frontal Gyrus 240, 25, 3 4.25 56
R Fusiform WM 38, 271, 221 4.06 83
R Entorhinal WM 20, 11, 228 3.99 110
R Lingual Gyrus 28, 261, 24 3.96 74
R Middle Temporal Gyrus 46, 263, 26 3.91 52
L Inferior Parietal Lobule 252, 241, 40 3.75 63
P-Tau & Fractional Anisotropy 6 6 6
P-Tau & Mean Diffusivity 6 6 6
Ab42 & Fractional Anisotropy
L,R Medial Frontal Gyrus 0 11 224 6.27 66
Ab42 & Mean Diffusivity 6 6 6
T-Tau/Ab42 & Fractional Anisotropy 6 6 6
T-Tau/Ab42 & Mean Diffusivity
L Temporal Lobe WM 244 236 213 7.71 11374
R Uncus 20 9 227 6.11 286
L Middle Frontal Gyrus WM 222 43 212 5.69 257
R Insula WM 36 26 11 5.50 229
R Supramarginal Gyrus WM 44 239 39 5.17 225
R Medial Frontal Gyrus WM 12 46 216 5.09 204
R Middle Temporal Gyrus 58 242 21 5.07 126
L Superior Temporal Gyrus 242 13 222 5.05 157
L Putamen 224 14 0 5.01 100
R Middle Temporal Gyrus 48 263 24 4.87 105
R Superior Temporal Gyrus WM 58 224 5 4.68 154
L Superior Temporal Gyrus WM 262 221 7 4.54 109
R Temporal Lobe WM 42 26 231 4.48 209
L Superior Temporal Gyrus WM 262 243 14 4.41 99
R Superior Occipital Gyrus WM 34 277 26 4.23 409
R Occipital Lobe WM 28 259 24 4.20 87
R Middle Temporal Gyrus WM 56 214 216 4.04 76
R Precentral Gyrus WM 34 222 51 3.91 100
L Frontal Lobe WM 230 235 39 3.82 100
R Cerebellum, Anterior Lobe 24 237 221 3.78 118
R Putamen 28 210 3 3.76 82
P-Tau/Ab42 & Fractional Anisotropy 6 6 6
P-Tau/Ab42 & Mean Diffusivity 6 6 6
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expected to shed further light on regional amyloid deposition in
the earliest stages of AD.
CSF Biomarkers in Cognitively Healthy Adults
In healthy older adults, levels of AD biomarkers measured in
CSF are related to age, cognition, structural brain volume, and
AD risk factors including APOE4 status [10,117,118] and family
history [51]. In our sample of healthy adults with elevated risk for
AD, we found significant positive correlations between age and T-
Tau, T-Tau/Ab42, and P-Tau181/Ab42. Alone, Ab42 was not
related to age. We also found that both T-Tau and Ab42 differed
between APOE4 carriers and non-carriers. Similar to previous
studies, Ab42 was lower in the carriers compared to non-carriers–
conceivably suggesting greater amyloid deposition in the group at
greater risk for AD. Interesting, we found that the APOE4 carriers
in this sample showed lower T-Tau compared to non-carriers.
These T-Tau findings are consistent with our previous report on
CSF biomarkers in middle-aged at-risk adults [119]. Although
APOE4 has been linked with higher T-Tau in some studies
[120,121], our sample differs in that all of the participants were
positive for parental family history of AD–a group which in middle
age shows higher T-Tau levels than the general population [51].
Further studies will be needed to dissociate the effects of APOE
and family history of AD on CSF biomarkers in middle-age.
All of the participants in our study tested cognitively normal.
Among the cognitive tests, only recognition memory was related to
any of the CSF measures. Participants with higher P-Tau181 and
P-Tau181/Ab42 levels had lower recognition on a list learning test
(RAVLT). Glodzik et al. have also found a relationship between P-
Tau (P-Tau231) and memory function [11], and combined use of
P-Tau181 and Ab42 has also been shown to predict longitudinal
subjective memory impairment in healthy elderly [122]. Because
our study was cross-sectional and restricted to cognitively healthy
participants, the limited range and variability of the cognitive
scores may have impacted our power to detect relationships
between the CSF biomarkers and other cognitive tests in our
study.
Previous brain imaging studies in healthy adults have found that
CSF biomarkers are related to volumetric measures. Healthy
elderly individuals from ADNI with low CSF Ab42 levels have
significantly higher whole brain loss over time, ventricular
expansion, and greater rates of hippocampal atrophy [14]. Fjell
et al. [13] also examined CSF biomarker and brain relationships in
healthy elderly individuals from ADNI. Lower Ab42 correlated
with 1-year change in several regions including putamen,
thalamus, superior temporal cortex, cingulate, and frontal brain
regions, whereas higher T-Tau/Ab42 was related to atrophy in
amygdala, paracentral cortex, and ventricular regions. Higher P-
Tau was related to 1-year change in amygdala, paracentral cortex,
posterior cingulate, and pallidum. Fjell et al.’s study is also one of
the few to show a relationship between P-Tau and cerebral white
matter, with higher P-Tau predicting lower white matter volume.
P-Tau reported in these studies was assayed for tau phosphory-
lated at threonine 181, although a similarly aged healthy cohort
evaluated at baseline and 2 years later by Glodzik et al. [11] has
shown that P-Tau231 is also associated with longitudinal medial
temporal lobe volume decline and memory function.
In our study of adults with parental family history of AD and a
high frequency of APOE4, we found relationships between CSF
measures and DTI in several brain regions shown in previous
volumetric studies of healthy participants, including temporal,
cingulate, and frontal cortices. We did not find a relationship
between the CSF biomarkers and gray matter volume (indexed by
T1-weighted imaging) in any brain regions, possibly due to the
younger age of our cohort in whom tissue changes are likely to be
more subtle and less easily detected with volumetric imaging.
Using DTI, we had the additional advantage of being able to
Table 3. Percent of regional overlap between statistical parametric mapping result maps.
T-Tau & MD T-Tau & Rad. T-Tau & Ax. T-Tau/Ab42 & Ax. T-Tau/Ab42 & Rad.
T-Tau/Ab42 & MD* 66% 74% 60% 85% 95%
T-Tau/Ab42 & Rad. Diff. 57% 70% 49% 68%
T-Tau/Ab42 & Ax. Diff. 54% 58% 58%
T-Tau & Ax. Diff. 84% 83%
T-Tau & Rad. Diff. 70%
All results maps were the product of a linear correlation analysis, where the CSF measures (T-Tau and T-Tau/Ab42) were used to predict the diffusion measures (MD,
axial and radial diffusivity). T-Tau: Total Tau; MD: Mean Diffusivity; Rad: Radial; Ax: Axial; Diff: Diffusivity.
*Result map shown in Figure 1.
doi:10.1371/journal.pone.0037720.t003
Table 2. Cont.
MNI coordinates
x y z Peak T value k (mm3)
NFL & Fractional Anisotropy
L Middle Temporal Gyrus WM 242 265 11 6.66 40
NFL & Mean Diffusivity – – –
MNI: Montreal Neurological Institute; k: cluster size; T-Tau: Total Tau; P-Tau: Phosphorylated Tau; WM: White Matter; L: Left; R: Right.
6No relationship with any regions at FDR corrected threshold p,.05.
2 No group differences in any region at FDR corrected threshold p,.05.
doi:10.1371/journal.pone.0037720.t002
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evaluate potentially subtle effects in white matter, and these
relationships were robust and widespread.
Limitations
While the results of this study are promising, potential
limitations should be noted. We adopted a voxel-wise approach
in order to assess the extent to which CSF biomarkers were related
to brain microstructure and volume across gray and white matter
tissue. While we took great care to evaluate for potential errors
during registration of the DTI maps to a common template,
methods that employ registration to a template may be susceptible
to subtle error and statistical effects may be influenced by the size
of smoothing filters used in voxel-wise analyses. As a further
comment on the DTI results, we would like to note that this study
used a tensor model which resolves a single fiber direction within
each voxel. We found very robust results when analyzing the MD,
axial, and radial diffusivity maps, compared to the FA maps. Due
to the complex architecture of white matter, employing FA derived
from the tensor model may not have captured the full information
available with alternative methods of DTI acquisition and higher
order modeling [123]. We should also note that our population
was composed solely of participants with parental family history of
AD and the frequency of APOE4 was 28%. While this group is at
increased risk for AD and thus provides a powerful cohort for
examining AD biomarkers, the lack of family history negative
participants and high frequency of APOE4 potentially limits the
generalizability of our results to a healthy population in addition to
limiting our ability to measure relationships between CSF
biomarkers and brain measures that are independent of AD risk.
Additionally, although our study was longitudinal in the sense that
baseline CSF was collected followed by MRI acquisition
approximately three and a half years later, simultaneous MRI
and CSF collection over two or more time points would have
yielded greater power to map out longitudinal change in these
measures. Based on the results of this study, additional longitudinal
work is warranted. Finally, while our results begin to address the
pattern of white matter changes that may occur in the earliest
stages of AD, employing white matter biomarker assays in larger
cohorts of older adults is expected to clarify the nature of white
matter changes in the earliest disease stages.
Summary
CSF biomarkers previously associated with AD are related to
brain tissue microstructure. This study supports an emerging
theory that brain white matter alterations are an early event in AD
pathogenesis. The mechanisms that underlie white matter
alterations and the nature of these alterations deserve further
study.
Supporting Information
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